⌕
Palvella Therapeutics · PVLA · Nasdaq
Tenet 34 · Weak
Compare
$144.60−5.17%At closeTenet 34 · Weak
$144.60−7.88 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Palvella Therapeutics (PVLA) Stock

Palvella Therapeutics (PVLA) closed at $144.60 on Nov 16, 2026; its Tenet Score is 34 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$144.60
Nov 16, 2026
Market cap
$1.6B
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
72.22 – 179.95
low → high
Tenet Score
34/100
Weak · 409 Healthcare peers

Industry: Pharmaceutical Preparations · see every company filed here →

Palvella Therapeutics, Inc. scores 34/100. Weak. Strongest on financial health, value is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 34 is built from 3 of 4 pillars, from 50% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
34/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
4
Quality
29
Health
68
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthCGrowth—MomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not reported in the company's filings for this period.
P/B
62.1×
cap ÷ fiscal 2025 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−149%
fiscal 2025
Operating margin
0.0%
before interest and tax
Net margin
0.0%
fiscal 2025
Current ratio
5.20
fiscal 2025
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 4y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipel…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 56 US ETFs · top wrappers by weightSee all ETFs holding PVLA →

Similar-sized companies in Pharmaceutical Preparations

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Palvella Therapeutics in?

Palvella Therapeutics is in the Healthcare sector and the Pharmaceutical Preparations industry.

What is Palvella Therapeutics' Tenet Score?

Palvella Therapeutics' Tenet Score is 34 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.